HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Clinical trials for HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) explained in plain language.
Never miss a new study
Get alerted when new HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) trials appear
Sign up with your email to follow new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo shows promise against aggressive head and neck cancer
Disease control Recruiting nowThis study tests whether giving two drugs—ficerafusp alfa and pembrolizumab—before surgery can shrink tumors in people with advanced head and neck cancer. About 32 participants with resectable, PD-L1-positive tumors will receive the combination, then have surgery. The main goal i…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Apr 29, 2026 01:37 UTC
-
Could less radiation mean better life for head and neck cancer patients?
Disease control Recruiting nowThis study looks at whether people with advanced head and neck cancer who had a good response to chemo-immunotherapy before surgery can safely get less radiation after neck lymph node removal. The goal is to keep cancer from coming back while improving quality of life. About 50 p…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Apr 29, 2026 01:37 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests an experimental drug called VMD-928, taken as a pill, either alone or with pembrolizumab (an immunotherapy). It is for adults with advanced solid tumors or lymphoma that have stopped responding to standard treatments. The goal is to find the safest dose and see i…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE1, PHASE2 • Sponsor: VM Oncology, LLC • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC